Skip to content

Compounded semaglutide and tirzepatide: what they are and where the rules stand

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Compounded semaglutide and tirzepatide are not FDA-approved, and FDA says a compounded drug is not a generic. FDA declared the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage resolved on February 21, 2025. That ended the conditions that had allowed compounding on a wide scale. By May 31, 2026, FDA had received 990 adverse event reports for compounded semaglutide.

Source: FDA

Key takeaways

  • Compounded semaglutide and tirzepatide are not FDA-approved, and FDA says a compounded drug is not a generic.
  • FDA says both shortages are resolved, which ended the conditions that allowed wide compounding.
  • FDA lists calling a compounded drug FDA-approved, or a generic version of a brand, as misleading.
  • FDA's advice: get a prescription from your doctor and fill it at a state-licensed pharmacy.
  • If you use a compounded product, take your questions to your prescriber or pharmacist.

Compounded semaglutide and compounded tirzepatide became common while the brand-name injections were in short supply. Those shortages are over. The legal rules have changed, and FDA has put out a series of statements about safety and advertising. This page sets out what the primary sources say, with dates. Each statement is quoted in the sources at the bottom of the page.

We don’t sell, rank or link to compounded products. This page has no offers and no prices for them.

What is a compounded drug?

FDA describes compounding as “generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.”

The words that matter are “tailored to the needs of an individual patient.” Compounding exists for people whose needs an approved product can’t meet. FDA’s guidance says so directly: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”

Is compounded semaglutide FDA-approved?

No, and neither is compounded tirzepatide. FDA says: “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”

They aren’t generics either. When asked whether a compounded drug is a generic, FDA says no. A generic is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and must meet its requirements. One of those is therapeutic equivalence to a brand-name drug, which means it has been shown to work the same way. A compounded drug is not approved by FDA.

That’s why the wording on a seller’s website matters, and why this site never describes a compounded product as equivalent to a brand. The FDA-approved medicines that contain semaglutide are Wegovy, Ozempic and Rybelsus. The FDA-approved medicines that contain tirzepatide are Zepbound and Mounjaro. Each one has its own label and its own approved uses.

Why did compounded GLP-1s become so common?

The shortage rules. Federal law limits compounders from making drugs that are essentially copies of commercially available or FDA-approved drugs. Those limits ease when the approved drug is on FDA’s drug shortage list. FDA explains that an outsourcing facility’s compounded drug “may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA’s drug shortage list.”

FDA says semaglutide injection products had been in shortage since 2022 because of increased demand. Tirzepatide injection was on the list too. While the shortages lasted, compounders could make versions that the copy rules would otherwise have limited.

When did the shortages end?

Tirzepatide. FDA first decided the tirzepatide injection shortage was resolved on October 2, 2024. It then looked again and issued a new decision on December 19, 2024, once more finding the shortage resolved. It gave compounders a wind-down period of enforcement discretion, which is a stretch of time when FDA chose not to act against them. That ran until February 18, 2025 for state-licensed pharmacies under section 503A, and until March 19, 2025 for outsourcing facilities under section 503B. A district court denied a preliminary injunction on March 5, 2025. FDA then confirmed the period had ended for 503A compounders and would end on March 19, 2025 for outsourcing facilities.

Semaglutide. FDA decided on February 21, 2025 that the shortage of semaglutide injection products was resolved. The wind-down ran until April 22, 2025 for 503A pharmacies and physicians, and until May 22, 2025 for 503B outsourcing facilities. A district court denied a preliminary injunction on April 24, 2025, and FDA confirmed those dates again.

FDA’s general rule: “When a drug shortage is resolved, FDA generally considers the drug to be commercially available.” Once that’s true, the copy rules apply again.

Can pharmacies still compound semaglutide or tirzepatide?

Compounding didn’t become illegal, but the room for it got much smaller. The two kinds of compounder follow different rules. The 503A and 503B page covers them in detail.

State-licensed pharmacies and physicians (503A). FDA has reminded these compounders of two conditions under section 503A. The drug is compounded for an individual patient after a prescription is received. And the compounder does not compound, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product. FDA has said that, at this time, it does not intend to act against a compounder that fills four or fewer prescriptions of such a product in a calendar month.

Adding an ingredient doesn’t automatically take a product outside the copy rule. FDA’s example is semaglutide combined with vitamin B12. It may still count as essentially a copy when it is given by the same route and the amounts are within 10% of the strengths of the commercially available products.

Outsourcing facilities (503B). These facilities may not compound from a bulk drug substance (the raw active ingredient) unless the substance is on FDA’s 503B bulks list or the drug is on the shortage list. In the same update FDA said: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”

What is the 2026 proposal on the 503B bulks list?

On May 1, 2026, FDA published a Federal Register notice proposing not to add semaglutide, tirzepatide and liraglutide to the 503B Bulks List. Its stated reason: it “tentatively finds no basis to conclude that there is a clinical need for an outsourcing facility to compound using” those substances. FDA added that it doesn’t consider shortages and backorders to fall within the meaning of clinical need.

This was a proposal open for public comment, not a final decision. A second notice on June 26, 2026 extended the comment period to July 30, 2026.

What safety concerns has FDA raised?

FDA keeps a page titled “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” These are its main points.

  • Adverse event reports. By May 31, 2026, FDA had received 990 reports of adverse events linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. FDA says these are likely underreported. Federal law doesn’t require state-licensed pharmacies that aren’t outsourcing facilities to send them in. FDA also says it isn’t always possible to tell whether an event came directly from the drug.
  • Dosing errors. FDA received several reports of adverse events, some needing a hospital stay, that may be related to dosing errors with compounded injectable semaglutide. Some came from patients measuring and injecting the wrong dose. In some cases health care professionals miscalculated the dose. Our dosing error tool explains how these mistakes happen.
  • Salt forms. FDA knows that some semaglutide products sold by compounders may be salt forms, including semaglutide sodium and semaglutide acetate. FDA says these “are different active ingredients than are used in the approved drugs.” It says it has no information on whether they work like the approved ingredient, and it knows of no lawful basis for using them in compounding.
  • Counterfeits. FDA knows of counterfeit Ozempic sold in the US. A counterfeit could have the wrong ingredients, too little, too much or no active ingredient, or other harmful ingredients.
  • “Research use” products. FDA has warned companies that illegally sold unapproved semaglutide, tirzepatide, retatrutide, survodutide or mazdutide falsely labeled “for research purposes” or “not for human consumption.” It urges consumers not to buy them.
  • Unapproved molecules. Retatrutide and cagrilintide cannot be used in compounding under federal law. Our pipeline page explains where those medicines stand.

More broadly, FDA warns that poor compounding practices can lead to contamination, or to a drug with too much or too little active ingredient.

What has FDA said about advertising?

Much of FDA’s action has been about marketing claims. On September 9, 2025, HHS and FDA announced a crackdown on misleading drug advertising aimed at consumers, including about 100 cease-and-desist letters. On February 6, 2026, FDA said companies cannot claim that compounded products are generic versions of, or the same as, drugs approved by FDA. They also cannot say that compounded drugs share an active ingredient with the FDA-approved drugs, or that compounded drugs are clinically proven to produce results for the patient.

On March 3, 2026, FDA announced 30 warning letters to telehealth companies over false or misleading claims about compounded GLP-1 products. The main problems were claims implying the products were the same as FDA-approved ones, and branding that hid where the product came from by suggesting the telehealth company was the compounder.

FDA’s list of claims telehealth companies must not make goes further. It includes saying a compounded drug is FDA-approved, saying it’s clinically proven to produce the same result as the approved drug, and saying it comes from an FDA-approved or FDA-licensed pharmacy. In FDA’s words: “FDA does not approve or license any facility.”

If a website makes any of these claims, treat it as a warning sign, the way FDA does. The page on how to verify a pharmacy lists the checks FDA and the National Association of Boards of Pharmacy describe.

What does FDA tell patients to do?

FDA’s advice is simple: “Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy.” If you buy online, it urges you to buy only from state-licensed pharmacies. Its BeSafeRx campaign teaches people how to buy prescription medicines online safely. FDA also asks you to report unexpected side effects through MedWatch, and to report websites you think are selling medicine illegally.

If you’re using a compounded product, this page is not a reason to stop or change anything on your own. Take your questions to your prescriber or pharmacist, including where the product is made and what its label says.

If price is the reason

Many people looked at compounded products because of cost. Before you decide the FDA-approved medicines are out of reach, check what they cost. Without insurance, the manufacturer self-pay programs start at $149 a month for the Wegovy pill and $299 a month for Zepbound. The without-insurance guide ranks the cash routes. The cost guide covers insurance and savings cards, and the cheapest path tool works through your situation. If you have Medicare, the Medicare page explains the GLP-1 Bridge.

Frequently asked questions

Is compounded semaglutide FDA-approved?

No. FDA says compounded drugs are not FDA-approved. That means the agency does not check their safety, effectiveness or quality before they're sold. This is true of compounded semaglutide and compounded tirzepatide alike. FDA also says telehealth companies must not claim a compounded drug has been FDA-approved or evaluated for safety and effectiveness.

Is compounded semaglutide a generic version of the brand drug?

No. FDA says a generic drug is approved under section 505(j) of the Federal Food, Drug, and Cosmetic Act and must establish therapeutic equivalence to a brand-name drug. In plain words, it has to be shown to work the same way. A compounded drug is not approved by FDA at all. FDA lists calling a compounded drug a generic version of an approved drug among the claims it considers false or misleading.

Is the semaglutide shortage over?

Yes, according to FDA. On February 21, 2025 the agency decided that the shortage of semaglutide injection products was resolved. They had been in shortage since 2022 because of increased demand. FDA's enforcement-discretion periods, a grace period for compounders, ended on April 22, 2025 for state-licensed pharmacies and physicians and on May 22, 2025 for outsourcing facilities.

Is the tirzepatide shortage over?

Yes, according to FDA. The agency first decided the tirzepatide injection shortage was resolved on October 2, 2024. It then looked again and issued a new decision on December 19, 2024 that the shortage is resolved. Enforcement discretion, the grace period for compounders, ended on February 18, 2025 for state-licensed pharmacies and on March 19, 2025 for outsourcing facilities.

Can a pharmacy still compound semaglutide or tirzepatide?

Federal law still allows some compounding, under tighter limits. Under section 503A, a drug is compounded for one patient based on a prescription, and the compounder may not regularly or in inordinate amounts make essential copies of a commercially available drug. FDA says outsourcing facilities may not compound from a bulk substance unless it is on the 503B bulks list or the shortage list. Semaglutide and tirzepatide are on neither.

Is adding vitamin B12 enough to make a compounded product different?

Not necessarily. FDA says a compounded product that combines semaglutide with another ingredient, such as vitamin B12, may still count as essentially a copy of a commercially available drug. That applies when it is given by the same route and the amounts are within 10% of the strengths of the commercially available products.

How many adverse events have been reported with compounded GLP-1 drugs?

By May 31, 2026, FDA had received 990 reports of adverse events (side effects or other harms) linked to compounded semaglutide and more than 730 linked to compounded tirzepatide. FDA says the real numbers are likely higher, because state-licensed pharmacies that are not outsourcing facilities don't have to report them. It also says a report doesn't prove the drug caused the event.

Can retatrutide be compounded?

No. FDA says retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition. FDA has also warned companies selling unapproved products labeled for research purposes, and it urges consumers not to buy them.

Does glp1doses list compounded GLP-1 sellers or prices?

No. This site records prices only for FDA-approved medicines. It does not name, rank or link to sellers of compounded products, and it earns nothing from them. This section is a neutral explainer of what FDA and other primary sources say. Decisions about any medicine belong with you and a licensed prescriber.

Sources (33)

  1. 1.
    FDA: Human Drug Compounding
    “Compounding is generally a practice in which a licensed pharmacist, a licensed physician or, in the case of an outsourcing facility, a person under the supervision of a licensed pharmacist, combines, mixes or alters ingredients of a drug to create a medication tailored to the needs of an individual patient.”
  2. 2.
    FDA: Compounding and the FDA: Questions and Answers
    “Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. Consumers and health care professionals rely on FDA’s drug approval process for verification of safety, effectiveness and quality.”
  3. 3.
    FDA: Compounding and the FDA: Questions and Answers
    “No. A generic drug is approved by FDA under 505(j) of the FD&C Act and meets all of the requirements of that section (including establishing therapeutic equivalence to a brand name drug, among others), while a compounded drug is not approved by FDA.”
  4. 4.
    FDA: Compounding and the FDA: Questions and Answers
    “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Unnecessary use of compounded drugs may expose patients to potentially serious health risks. For example, poor compounding practices can result in serious drug quality problems, such as contamination or a drug that contains too much or too little active ingredient. This can lead to serious patient injury and death.”
  5. 5.
    FDA: Compounding and the FDA: Questions and Answers
    “Generally, state boards of pharmacy have primary responsibility for the day-to-day oversight of state-licensed pharmacies that are not registered with FDA as outsourcing facilities. FDA does conduct surveillance and for-cause inspections of state-licensed pharmacies that are not registered as outsourcing facilities.”
  6. 6.
    FDA: Compounding and the FDA: Questions and Answers
    “Outsourcing facilities are a category of compounders established in 2013 by the Drug Quality and Security Act. Outsourcing facilities are inspected by FDA according to a risk-based schedule and are subject to increased quality standards. [...] Facilities that register with FDA as outsourcing facilities under section 503B are primarily overseen by FDA and inspected by FDA according to a risk-based schedule.”
  7. 7.
    FDA: Compounding and the FDA: Questions and Answers
    “Quality standards for compounded drugs differ depending on the setting where compounding occurs. Drugs compounded in outsourcing facilities are subject to current good manufacturing practice (CGMP) requirements. By contrast, drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, in accordance with the conditions of section 503A of the FD&C Act, are not.”
  8. 8.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “Under section 503A: The drug product is compounded for an individual patient based on receipt of a prescription. The compounder does not compound, regularly or in inordinate amounts, any that are essentially copies of a commercially available drug product.”
  9. 9.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “For example, FDA may consider a compounded drug product that combines semaglutide API and another API, such as vitamin B12 (cyanocobalamin), to be essentially a copy of a commercially available drug product when the: drug products are used by the same route of administration – the compounded drug product is given the same way as the commercially available drug products, such as an injectable drug products are the same, similar or easily substitutable strength – the amounts of semaglutide and vitamin B12 in the compounded drug product are within 10% of the strengths of the respective commercially available drug products.”
  10. 10.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “FDA has stated, at this time, it does not intend to take action against a compounder for compounding a drug product that is essentially a copy of a commercially available drug product regularly or in inordinate amounts if the compounder fills four or fewer prescriptions of that compounded drug product during a calendar month.”
  11. 11.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “Outsourcing facilities are restricted from compounding drugs using bulk drug substances (or API) unless: the bulk drug substance appears on a list identifying bulk drug substances for which there is a clinical need, which is referred to as the 503B bulks list or the drug compounded from the bulk drug substance is on FDA’s drug shortage list at the time of compounding, distribution and dispensing. Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
  12. 12.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “FDA re-evaluated its determination from October 2, 2024, on the status of the tirzepatide shortage. Today, FDA has issued a new decision determining the tirzepatide injection shortage is resolved. [...] For a state-licensed pharmacy under section 503A of the FD&C Act compounding, distributing or dispensing tirzepatide injections within 60 calendar days from today’s announcement, until February 18, 2025. For outsourcing facilities under section 503B compounding, distributing or dispensing tirzepatide injections within 90 calendar days from today’s announcement, until March 19, 2025.”
  13. 13.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “Tirzepatide: On March 5, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:24-cv-00953 (N.D. Tex.). Therefore, consistent with FDA’s February 11, 2025 update: For a state-licensed pharmacy or physician compounding under section 503A of the FD&C Act, the period of enforcement discretion described below has ended. For outsourcing facilities under section 503B, FDA does not intend to take action against compounders for violations of the FD&C Act arising from conditions that depend on tirzepatide injection products’ inclusion on FDA’s drug shortage list until March 19, 2025.”
  14. 14.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “FDA has determined the shortage of semaglutide injection products, a glucagon-like peptide 1 (GLP-1) medication, is resolved. Semaglutide injection products have been in shortage since 2022 due to increased demand. [...] For a state-licensed pharmacy or physician compounding under section 503A of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved product within 60 calendar days from today’s announcement, until April 22, 2025. For outsourcing facilities under section 503B of the FD&C Act: compounding, distributing or dispensing semaglutide injection products that are essentially a copy of an FDA-approved drug product within 90 calendar days from today’s announcement, until May 22, 2025.”
  15. 15.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “On April 24, 2025, the district court denied the plaintiffs’ preliminary injunction motion in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.) regarding compounded semaglutide. Therefore, consistent with FDA’s March 10, 2025, update: For a state-licensed pharmacy or physician compounding, dispensing or distributing semaglutide injection products under section 503A of the FD&C Act, the period of enforcement discretion (described below) has ended. For outsourcing facilities compounding, distributing or dispensing semaglutide injection products under section 503B, FDA does not intend to take action for violations of the FD&C Act arising from conditions that depend on semaglutide injection products’ inclusion on FDA’s drug shortage list until May 22, 2025.”
  16. 16.
    FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize
    “Section 503A of the FD&C Act includes restrictions on compounding drugs that are essentially copies of a commercially available drug. When a drug shortage is resolved, FDA generally considers the drug to be commercially available. Certain amounts are permissible under the law as long as the compounding is not done “regularly or in inordinate amounts.” Section 503B of the FD&C Act restricts outsourcing facilities from making compounded drugs that are essentially a copy of one or more FDA-approved drugs. Among other things, this means the compounded drug may not be identical or nearly identical to an FDA-approved drug unless the approved drug is on FDA’s drug shortage list.”
  17. 17.
    Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    “The Food and Drug Administration (FDA, the Agency, or we) is evaluating substances that have been nominated for inclusion on a list of bulk drug substances (active pharmaceutical ingredients) for which there is a clinical need for outsourcing facilities to use in compounding (the 503B Bulks List). This notice identifies three bulk drug substances that FDA has considered and proposes not to include on the 503B Bulks List: semaglutide, tirzepatide, and liraglutide.”
  18. 18.
    Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act
    “For the reasons stated above, FDA tentatively finds no basis to conclude that there is a clinical need for an outsourcing facility to compound using the following bulk drug substances: semaglutide, tirzepatide, and liraglutide. Therefore, we propose not to include these bulk drug substances on the 503B Bulks List. [...] However, FDA does not interpret such issues, such as shortages and backorders, to be within the meaning of “clinical need” for compounding with a bulk drug substance.”
  19. 19.
    Federal Register: List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period
    “The Food and Drug Administration (FDA or the Agency) is extending the comment period for the notice entitled “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act” that appeared in the Federal Register of May 1, 2026. [...] The Agency is taking this action in response to a request for an extension to allow interested persons additional time to submit comments. [...] FDA is extending the comment period on the notice published in the Federal Register of May 1, 2026 (91 FR 23431). Either electronic or written comments must be submitted by July 30, 2026.”
  20. 20.
    FDA: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s
    “The U.S. Food and Drug Administration today announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 products offered on their websites. [...] This is the second group of warning letters sent to telehealth firms since the agency launched in September a crackdown on misleading direct-to-consumer pharmaceutical advertisements. [...] Primary violations identified in the letters included making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder.”
  21. 21.
    FDA: FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs
    “The FDA is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA. They also cannot state compounded drugs use the same active ingredient as the FDA-approved drugs or that compounded drugs are clinically proven to produce results for the patient.”
  22. 22.
    FDA: FDA Launches Crackdown on Deceptive Drug Advertising
    “The U.S. Department of Health and Human Services and the Food and Drug Administration today announced sweeping reforms to rein in misleading direct-to-consumer pharmaceutical advertisements. Today, the FDA is sending thousands of letters warning pharmaceutical companies to remove misleading ads and issuing approximately 100 cease-and-desist letters to companies with deceptive ads.”
  23. 23.
    FDA: FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs
    “The agency reminds telehealth companies not to market compounded GLP-1 drugs to consumers with false or misleading claims, including: using branding on their website that falsely or misleadingly implies the telehealth company is the compounder. describing a compounded drug as a generic version of an FDA-approved drug or the same as a drug approved by FDA. Generic drugs are approved by FDA prior to marketing, while a compounded drug is not approved by FDA. claiming a compounded drug has been FDA-approved or has otherwise been evaluated for safety and effectiveness when they are not. Compounded drugs are not reviewed by the agency for safety, effectiveness or quality prior to marketing. describing a compounded drug as clinically proven to produce the same result as the FDA-approved drug. claiming a compounded drug is sourced from an FDA-approved or FDA-licensed pharmacy or outsourcing facility. FDA does not approve or license any facility.”
  24. 24.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “However, federal law does not require state-licensed pharmacies that are not outsourcing facilities to submit adverse events to FDA so it is likely that adverse events from compounded versions of these drugs are underreported. [...] As of May 31, 2026, the FDA has received: 990 reports of adverse events associated with compounded semaglutide. more than 730 reports of adverse events associated with compounded tirzepatide. It is not always possible to determine if the adverse event directly resulted from use of the drug or if other factors may have contributed to these adverse events.”
  25. 25.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “The agency is aware that some semaglutide products sold by compounders may be the salt forms. These salt forms, including semaglutide sodium and semaglutide acetate, are different active ingredients than are used in the approved drugs. The agency does not have information on whether these salts have the same chemical and pharmacologic properties as the active ingredient in the approved drug, and we are not aware of any lawful basis for their use in compounding.”
  26. 26.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors associated with compounded injectable semaglutide products. These dosing errors resulted from patients measuring and self-administering incorrect doses of the drug, and in some cases, health care professionals miscalculating doses of the drug.”
  27. 27.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition.”
  28. 28.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA is aware of counterfeit Ozempic marketed in the U.S. Counterfeit drugs claim to be authentic, but could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal.”
  29. 29.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “FDA has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled “for research purposes” or “not for human consumption.” These products have been sold directly to consumers for human use with dosing instructions. The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.”
  30. 30.
    FDA: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
    “Patients should obtain a prescription from their doctor and fill the prescription at a state-licensed pharmacy. [...] The agency urges consumers to be vigilant when purchasing drugs online and only purchase from state-licensed pharmacies.”
  31. 31.
    FDA: BeSafeRx: Your Source for Online Pharmacy Information
    “FDA’s BeSafeRx campaign helps consumers learn about how to safely buy prescription medicines online. [...] If you have an unexpected experience or side effect associated with the use of a medicine, please report that information to FDA using MedWatch. If you encounter websites that you think are illegally selling medicine, please report unlawful sales.”
  32. 32.
  33. 33.